Table S2. Comparison of TAVR with SAVR at 30-days after exclusion of STACCATO trial.
| Outcome | Studies | Event rate | Odds ratio (95% CI) | I2 | Chi2 | Intergroup difference P value | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| TAVR | SAVR | Overall | Low-risk | Intermediate-risk | ||||||
| All-cause mortality | 5 | 67/3,241 (2.1%) | 74/3,084 (2.4%) | 0.87 (0.61–1.26) | 0.44 (0.20–0.97) | 1.04 (0.71–1.51) | 6% | 4.24 | 0.06 | |
| Cardiac mortality | 5 | 59/3,241(1.8%) | 64/3,084(2.1%) | 0.90 (0.63–1.29) | 0.46 (0.21–1.03) | 1.07 (0.71–1.60) | 0% | 3.44 | 0.07 | |
| Stroke | 5 | 114/3,241 (3.5%) | 144/3,084 (4.7%) | 0.72 (0.50–1.04) | 0.57 (0.22–1.49) | 0.74 (0.48–1.15) | 37% | 6.39 | 0.62 | |
| Major bleeding | 5 | 261/3,241 (8.1%) | 706/3,084 (22.9%) | 0.32 (0.11–0.91) | 0.25 (0.11–0.56) | 0.45 (0.05–3.84) | 97% | 134.4 | 0.61 | |
| Acute kidney injury | 5 | 38/3,241 (1.2%) | 102/3,084 (3.3%) | 0.36 (0.24–0.52) | 0.27 (0.13–0.55) | 0.40 (0.26–0.62) | 0% | 2.14 | 0.36 | |
| Atrial fibrillation | 5 | 303/3,241 (9.3%) | 1072/3,084 (34.8%) | 0.17 (0.12–0.24) | 0.13 (0.10–0.18) | 0.23 (0.16–0.34) | 80% | 19.95 | 0.02 | |
| Permanent pacemaker | 5 | 513/3,241 (15.8%) | 182/3,084 (5.9%) | 3.31 (1.64–6.66) | 4.32 (1.51–12.36) | 2.51 (0.67–9.37) | 92% | 48.22 | 0.53 | |
| Major vascular complications | 5 | 179/3,241(5.5%) | 91/3,084 (3.0%) | 2.09 (1.18–3.71) | 1.39 (0.87–2.22) | 2.91 (0.86–9.83) | 70% | 13.27 | 0.27 | |
| Mod-severe paravalvular regurgitation | 4 | 64/2,883 (2.2%) | 8/2,495 (0.3%) | 5.69 (2.00–16.18) | 1.66 (0.06–45.37) | 7.15 (3.24–15.77) | 31% | 4.36 | 0.40 | |
CI, confidence interval; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.